# Top 10 intervention extracts from Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση_cleaned.json

=== Ranked Intervention 1 (Extract #1, Treatment) — Score: 8 ===
Arnedos M, Popat S,Platinum-based chemotherapy in triple-negative breast cancer.Ann Oncol.
2008 Nov;19(11):1847-52. Epub 2008 Jun 20
75.Angelo Di Leo, Henry L. Gomez, Zeba Aziz. Phase III, Double-Blind, Randomized Study Comparing
Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast
Cancer J Clin Oncol 26:5544-5552,2008
76.Kimberly L. Blackwell, Harold J. Burstein, Anna Maria Storniolo Randomized Study of Lapatinib Alone or
in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic
Breast Cancer. J Clin Oncol 28:1124-1

=== Ranked Intervention 2 (Extract #4, Treatment) — Score: 8 ===
, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma N Engl J Med. 2008 Jul
2. Martin RC, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg
Oncol Clin N Am 2002;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomi

=== Ranked Intervention 3 (Extract #2, Treatment) — Score: 7 ===
Anna Maria Storniolo Randomized Study of Lapatinib Alone or
in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic
Breast Cancer. J Clin Oncol 28:1124-1130,2010
77.Kaufman B, Mackey JR, Clemens MR Trastuzumab plus anastrozole versus anastrozole alone for the
treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone
receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin
Oncol. 2009 Nov 20;27(33):5529-37. Epub 2009 Sep 28
solid tumours: integrated analysis of three phase 1-2 tr

=== Ranked Intervention 4 (Extract #23, Treatment) — Score: 7 ===
Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4

=== Ranked Intervention 5 (Extract #24, Treatment) — Score: 7 ===
ugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK,|n JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK,
Row 3: Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus|
Row 4: fluoxymesterone for the treatment of cancer anorexia/cachexia. J ClinOncol. 1999;17(10):3299.|
Row 5: |
Row 6: 15. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. .ROMANA 3: a phase 3 safety extension|
Row 7: study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.AnnOncol.|
Row

=== Ranked Intervention 6 (Extract #26, Treatment) — Score: 7 ===
acute confusional states).JAMA. 1987;258(13):1789.
Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.
Row 4: 5. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8:

=== Ranked Intervention 7 (Extract #27, Drug) — Score: 7 ===
HR 0.70 (95% CI, 0.58–0.83)] , όσο και στον συνολικό πληθυσμό [18.7 (15.6–21.3) vs 11.9 (10.7–13.3); 0.65 95% CI,
Στους HER-2 θετικούς όγκους, που έχουν υποτροπιάσει μετά από θεραπεία 1ης γραμμής στην οποία
συμπεριλαμβανόταν το Trastuzumab, δύναται να λάβουν συνέχιση θεραπείας, με τον ADC (Antibody Drug
Conjugate) παράγοντα Trastuzumab Deruxtecan,το οποίο έλαβε πρόσφατα έγκριση από τον FDA σύμφωνα με την
μελέτη φάσης 2 Destiny PanTumor 02, στην οποία εντάχθηκαν από τους 268 ασθενείς με διάφορους συμπαγείς
όγκους 40 ασθενείς με καρκίνο του ενδομητρίου, με ικανοποιητικά ποσοστά ανταποκρίσεων (ORR: 5

=== Ranked Intervention 8 (Extract #14, Treatment) — Score: 6 ===
καθώς και ειδικά στους
ογκολογικούς ασθενείς μέσω της πανευρωπαικής μελέτης NACASY [12] και άλλων μελετών [13-14]. Η
σ υνιστώμενη δόση της ναλοξεγκόλης, είναι 25 mg άπαξ ημερησίως [24].
1. ESMO Minimum Clinical Recommendations: Chemotherapy-induced nausea and vomiting.
2. Gralla RJ: New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29 (Suppl 4): 119–24.3.
3. Licitra L, Spinazze S, Roila F: Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive

=== Ranked Intervention 9 (Extract #38, Therapy) — Score: 6 ===
ολογικούς ασθενείς μέσω της πανευρωπαικής μελέτης NACASY [12] και άλλων μελετών [13-14]. Η
σ υνιστώμενη δόση της ναλοξεγκόλης, είναι 25 mg άπαξ ημερησίως [24].
1. ESMO Minimum Clinical Recommendations: Chemotherapy-induced nausea and vomiting.
2. Gralla RJ: New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29 (Suppl 4): 119–24.3.
3. Licitra L, Spinazze S, Roila F: Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015

=== Ranked Intervention 10 (Extract #39, Therapy) — Score: 6 ===
τώμενη δόση της ναλοξεγκόλης, είναι 25 mg άπαξ ημερησίως [24].
1. ESMO Minimum Clinical Recommendations: Chemotherapy-induced nausea and vomiting.
2. Gralla RJ: New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29 (Suppl 4): 119–24.3.
3. Licitra L, Spinazze S, Roila F: Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081-90.
5. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant an

